New dengue virus inhibitors targeting NS3-NS5 interaction identified by <i>in silico</i> screening.

ABSTRACT: Dengue virus (DENV) poses a major public health concern as it is responsible for approximately 100 million human infections annually. Since no antiviral drugs are currently available to treat DENV infection, the development of effective therapeutic strategies is urgently needed. For anti-DENV drug discovery, the interaction between DENV NS3 and NS5 proteins represents an attractive target, as it is essential for viral replication and is highly conserved across all DENV serotypes. In this study, we report two distinct virtual screenings of commercially available drug-like compounds, which were performed to identify inhibitors of the NS3-NS5 interaction. Both screening approaches led to the identification of hit compounds that were able to reduce NS3-NS5 binding in vitro in a dose-dep

SUBMITTER: Nannetti G 

PROVIDER: S-EPMC12615485 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature